Topical agents freshly formulated in a cream base vehicle as well as commercial topical preparations were used to evaluate in mice the responsiveness of experimental surgical wounds infected with Staphylococcus aureus or Pseudomonas aeruginosa to chemotherapy. The responsiveness of the infections to therapy or the efficacy of a topical agent was assessed primarily by means of wound counts of the infecting organism before and after the employment of an immediate (prophylactic) or delayed (therapeutic) treatment regimen. From tests of several concentrations of an agent formulated in the vehicle, a median effective dose could be determined. In the case of the lethal P. aeruginosa infection, a median protective dose could be determined. Both infections were found to be quite susceptible to treatment with those topical agents that demonstrated good activity in vitro against the test organisms. The results of the investigation indicated that the model infections were suitable for the screening of potential topical agents in vivo.
In the preceding paper experimental surgical-wound infections in mice were described and characterized (6) . In addition, a rapid method for quantitating bacteria in the wound infections was presented. In this paper the response of the surgical-wound infections to chemotherapy with various topical antimicrobial agents is explored. Freshly formulated antibacterial agents, commonly administered topically, as well as commercial topical antimicrobial products were employed in the study. These topical formulations were used not only for evaluating the responsiveness of the experimental infections to chemotherapy but also for demonstrating how, using standardized methodology, the model infections can be employed to assess various measures oftopical efficacy.
MATERIALS AND METHODS Antibacterial agents. The antibiotics and chemicals used in this study were gentamicin sulfate, 634 ,ug/mg (Schering Corp.); polymyxin B sulfate, 7, 956 U/mg (Pfizer Laboratories); neomycin sulfate, 654 ,ug/mg (E. R. Squibb & Sons); zinc bacitracin, 47.7 U/ mg (Commercial Solvents); gramicidin, 943 jAg/mg (E. R. Squibb & Sons); nitrofurazone (Eaton Laboratories); and triclobisonium chloride (Roche Laboratories). The agents were supplied as powders or crystals and, for testing in vivo, were formulated at the desired concentration on a weight basis in an emulsion-type cream base vehicle containing promulgen, protopet, sorbitol solution, silicone antifoam, distilled water, and methyl and ethyl parabens.
Commercial products. These products, with the active ingredients listed, were purchased on the open market: Neosporin ointment (Burroughs Wellcome Co.), consisting of (per gram) 5,000 U of polymyxin B sulfate, 400 U of zinc bacitracin, and neomycin sulfate equivalent to 3.5 mg ofneomycin base; Mycolog cream (E. R. Squibb & Sons), consisting of (per gram) 100,000 U of nystatin, 0.25 mg ofgramicidin, and neomycin sulfate equivalent to 2.5 mg of neomycin base, including 0.1% triamcinolone acetonide; Polysporin ointment (Burroughs Wellcome Co.), consisting of (per gram) 10,000 U of polymyxin B sulfate and 500 U of zinc bacitracin; Furacin topical cream (Eaton Laboratories), consisting of 0.2% nitrofurazone; Garamycin cream (Schering Corp.), consisting of 0.1% gentamicin sulfate; and Triburon ointment (Roche Laboratories), consisting of 0.1% triclobisonium chloride. Evaluation of antibacterial activity in vitro. Minimal inhibitory concentrations (MIC) were determined by the conventional twofold dilution method, using antibiotic assay broth (BBL) as previously described (3) . Aliquots from all tubes showing no visible growth were plated on antibiotic assay seed agar (BBL) to determine the minimal bactericidal concentration (MBC). Antibacterial agents were dissolved in 0.05 M phosphate buffer, pH 7.0, prior to being evaluated in vitro.
Evaluation of efficacy in vivo. Details of the experimental Staphylococcus aureus and Pseudomonas aeruginosa surgical-wound infections were presented in the preceding paper (6) . aliquots of wound washings and bacterial inocula containing 50 to 300 viable organisms were placed on brain heart infusion agar plates and spread over the surface of the agar. The plates were incubated at 37 C for 48 h. The number of colonies formed after incubation was compared with control counts obtained when washings were omitted.
RESULTS
The activity in vitro of several antibacterial agents, commonly utilized topically, against the two test organisms used in the surgicalwound infections is shown in Table 1 . The results indicate that the agents tested varied considerably in their activity against the test organisms. Against S. aureus, triclobisonium and gentamicin were the most active agents tested, exhibiting MIC values of <1.0 ,ug/ml. Nitrofurazone and neomycin also demonstrated good activity, whereas gramicidin and polymyxin B were less active. Against P. aeruginosa, gentamicin and polymyxin B were the most active agents. Neomycin and triclobisonium were also active, whereas the other agents were essentially inactive. With the exception of the activity of neomycin and gentamicin against P. aeruginosa, MBC values for the various agents were not markedly different from MIC values.
Several commercial topical preparations were evaluated in the experimental infections to determine the responsiveness of the infections to treatment with products specifically marketed for use against local infections. The results (Table 2) indicate that most of the products were efficacious against the S. aureus infection. All the products except the nitrofurazone formulation were extremely effective in inhibiting the growth of the test organism in the wound when the immediate-treatment schedule was followed; the nitrofurazone prod- uct was less effective than the other products. In the more stringent evaluation that occurred when treatment was delayed, all the products except the nitrofurazone preparation produced a significant reduction in the S. aureus wound count. The products were more diversified in their activity against the experimental P. aeruginosa infection. In the evaluation of prophylactic activity, i.e., with the immediatetreatment schedule, gentamicin and the two combination products were quite effective, the triclobisonium ointment was moderately active, and the nitrofurazone cream was essentially inactive. However, under the rigorous assessment of bactericidal efficacy that occurred when treatment was delayed, only the gentamicin formulation was efficacious.
To evaluate further the effectiveness of the experimental infections in assessing the efficacy of topical antibacterial agents, several of the agents used in commercial products were formulated at various concentrations near the "use" level in a compatible cream base vehicle and were tested in the model infections. The results of this abbreviated dose response study are presented in Table 3 . In general, the two infections were quite responsive to therapy with the various series of formulations and demonstrated approximately 2 log1O differences in bacterial wound counts when treated with two or three 10-fold decrements of the agent being evaluated. Neomycin formulations were the notable exception to this observation, exhibiting modest differences in wound counts in the S. aureus infection when applied prophylactically and in the P. aeruginosa infection when applied therapeutically. As was expected, with delayed treatment, larger concentrations of the various agents were required to produce significant responses in the infections than were required with the immediate-treatment regimen.
For a definitive comparison of the efficacy of different antibacterial agents in the experimental infections, a method of assessing activity based on the EDO was employed. At least three concentrations of an agent, formulated at fourto fivefold increments in the cream base vehicle, were tested. The EDO was defined as the concentration that produced a 3 log10 inhibition or reduction in the wound count of the infecting organism in 50% of mice. The results of a typical experiment are presented in Table 4 . Against the S. aureus infection, gentamicin and neomycin demonstrated equivalent activity when the immediate-treatment schedule was followed; however, gentamicin was more efficacious than neomycin when delayed treatment was employed. Bacitracin was not as efficacious as either of the other two antibiotics. Against the P. aeruginosa infections, polymyxin B was the most efficacious agent, demonstrating the same ED50 with both the immediate-and delayed-treatment schedules. Gentamicin was more active than neomycin but less active than polymyxin B.
In using inhibition and reduction of bacterial wound counts as criteria of formulation effi- be expected from its lack of activity in vitro and in vivo against P. aeruginosa in earlier studies, was not active at the concentrations tested. DISCUSSION Although there is some controversy as to the effectiveness of topical chemotherapy in certain types of local infections, there are several clinical situations in which topical therapy is apparently beneficial (1, 2, 5, 7). Topical antimicrobial formulations are widely used in the field of dermatology (9) . Because problems related to the development of resistance, sensitization, toxicity, and other undesirable effects have been encountered with several of the substances commonly used topically, the search has continued for new and more efficacious substances that can be utilized as topical chemotherapeutic agents.
The model infections described herein have been established for use as a screening tool for identifying and evaluating substances that may be employed as topical antibacterial agents. By utilizing standardized materials and methods, we have sought to eliminate some of the variables associated with the evaluation of topical antibacterial formulations, with the ultimate aim of bringing the most efficacious candidates to clinical trials in which the final assessment of efficacy must be made.
The primary purpose of this study was to evaluate the response of the model infections to treatment with various topical antimicrobial agents and preparations, most of which are employed in the clinic. Since topical agents may be either synthetic compounds or antibiotics, representatives of both types were included in this study. The results obtained indicate that the infections are quite responsive to treatment with efficacious topical agents of various potencies. In addition, various levels of efficacy could be detected, as determined by inhibition or reduction of bacterial wound counts and, in the case of the P. aeruginosa infection, by the survival of lethally infected mice. Furthermore, the responsiveness of the experimental infections to treatment with various concentrations of the commercial topical agents allowed the determination of ED50. Although an ED,0 was arbitrarily defined, its determination permits a more definitive and valid comparison of the activities of various agents than does the use of single concentrations of agents. In the case of the P. aeruginosa infection, the determination of PDo also aids in the evaluation of the topical efficacy of test substances. Results obtained from the screening of newly synthesized compounds indicate that the model infections are indeed useful in assessing the topical efficacy of potential agents (unpublished data).
For most of the topical agents employed in this study, there appeared to be some correlation between activities in vitro and in vivo. Agents that exhibited low MICs against a particular test organism in vitro usually demonstrated good efficacy when the immediate (prophylactic)-treatment schedule was followed for the experimental infection with that same organism; conversely, agents inactive in vitro showed little or no efficacy in vivo. The correlation was also observed with MBCs. Agents that demonstrated low MBCs in vitro were found to be efficacious when the delayed (therapeutic)-treatment schedule was followed; agents with high MBCs usually showed no activity in vivo. Thus, to some extent, the efficacy of an agent could be predicted from its activity in vitro.
Our experience to date in evaluating new compounds has revealed several potential agents that exhibited marked activity in vitro but were relatively ineffective in the experimental infections (unpublished data). Other investigators have made similar observations (4). Although both evaluations, in vitro and in vivo, involve direct contact between the antibacterial agent and the microorganism, the conditions in the infected wound are more complex than those found in the test tube and may affect adversely the activity of an antibacterial agent. One criticism commonly leveled when topical chemotherapy is studied in animals is that the topically administered drug has probably been ingested by the animals. Obviously, this can be a serious problem, but in our experience it is only occasionally encountered. For example, in this study, only mice treated with the commercial gentamicin formulation were observed ingesting it from the backs of cagemates. Because the ingestion of agents that are active when administered orally can interfere drastically with the evaluation of the substance as a topical agent, measures must be taken to prevent such ingestion. In the case of the gentamicin formulation, the problem was resolved by isolating the treated mice in small individual cages in which movement was severely restricted. Other means of preventing ingestion are the use of restrainers, collars, or coverings for the treatment site or the addition to the formulation of some inert chemical that discourages ingestion. It should be emphasized that the problem of ingestion occurs only infrequently with most of the commonly used topical preparations and vehicles.
Other criticisms sometimes raised when the efficacy of a topical formulation is evaluated culturally are that the activity observed may be due to residual drug and drug carry-over or to systemic activity resulting from topical absorption. In some instances these criticisms may be valid. Therefore, in evaluating topical chemotherapy on a cultural basis, it is necessary to demonstrate that these factors are not involved in the efficacy produced. Simple measures such as those employed in this study can be used to eliminate the possibility that drug carry-over and systemic activity have participated in the cultural results. In the case of residual drug and drug carry-over, there are various preventive measures that can be taken to reduce or abolish their involvement in the cultural evaluation. For example, substantial amounts of residual formulation should be removed prior to culturing a lesion, there should be a definite interval between the termination of therapy and the beginning of cultural evaluations, and the cultural procedures should employ several dilutions before plating.
Admittedly, the quantity of formulation applied to each wound as part of the experimental procedure is somewhat large, being analogous to applying 1.5 kg of formulation on a 77-kg human. However, we have found that it is necessary to apply a formulation in the experimental wound rather heavily in order to obtain a therapeutic response. Since the mice are caged in groups of 10, there is, obviously, some loss of formulation from the treated site. But, as the data show, the variation in bacterial wound counts between mice in a group is less than might be expected considering the conditions employed.
It should be noted that antimicrobial agents formulated for topical usage, in contrast to parenterally and orally administered agents, are often used at the same concentration in both animals and humans. The amount of drug applied and the frequency of treatment are usually determined by the size, type, and nature of the superficial infection being treated and not by the species of the host. Thus, in this study commercial topical antimicrobial preparations, intended for human use, were applied "as is" on the infected surgical wounds. In addition, freshly prepared formulations were made with the antimicrobial agent incorporated within the range of the "use concentration."
The surgical-wound model, in addition to its use in the evaluation of the topical antibacterial activity of test substances, has several other applications. For example, a subjective evaluation of the effect of a particular substance on wound healing can be made by examining the gross appearance of the wound at various intervals after treatment. Moreover, the application of the test material to the denuded suface of the wound can reveal topical absorption and toxicity. Finally, the model infections can be used to evaluate the activity of a substance that has been administered parenterally (unpublished data).
Although the surgical-wound model can provide useful and valuable information about the effect of topical treatment in mice, as mentioned previously, the ultimate determination of topical efficacy and safety must be made in humans.
